Abstract:Melanoma of the uveal tract or uveal melanoma (UM) originates from melanocytes of the eye and is the most common intraocular malignancy in adults. Despite considerable advances in diagnostic procedures and treatments, prognosis remains poor in those with advanced disease. Accordingly, although current treatments have an excellent local disease control rate, approximately 50% of patients develop metastatic relapse within 10 years. The high risk for metastatic disease with a variable and often long latency period is thought to be due to early spread of cancer cells disseminating into organs such as the liver, followed by a period of dormancy, before the eventual emergence of radiologically measurable disease. Early detection of disease relapse or metastasis is therefore crucial to allow timely treatment and ultimately improve patient outcome. Recently, advances in minimally-invasive liquid biopsy techniques and biomarkers such as circulating tumor DNA (ctDNA) have demonstrated potential to transform the field of cancer care by aiding diagnosis, prognosis and monitoring of various cancer types. UM is particularly suitable for ctDNA-based approaches due to the relatively well-characterized spectrum of genetic mutations, along with the inherent difficulties and risks associated with getting sufficient tumor samples via traditional biopsy methods. Key potential advantage of ctDNA are the detection of molecular residual disease (MRD) in patients post definitive treatment, and in the early identification of metastasis. This is particularly relevant contemporarily with the recent demonstration of tebentafusp improving survival in metastatic UM patients, and opens avenues for further research to investigate the potential utilization of tebentafusp combined with ctDNA-based strategies in adjuvant settings and early intervention for MRD. The present review illustrates the current understanding of ctDNA-based strategies in UM, discusses the potential clinical applications, explores the potential of utilizing ctDNA in UM MRD in the context of an ongoing clinical trial, and highlights the challenges that need to be overcome prior to routine clinical implementation.

Application of CTCF snare protein in preparation of anti-uveal melanoma medicine

CDDP Inhibition of Telomerase Activity in Uveal Melanoma Cells

An Artificial CTCF Peptide Triggers Efficient Therapeutic Efficacy in Ocular Melanoma

CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma

Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma

Proteomics Analysis: Inhibiting the Expression of P62 Protein by Chloroquine Combined with Dacarbazine Can Reduce the Malignant Progression of Uveal Melanoma

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGFβR1, GNAQ, WASL, and RAC1

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF beta R1, GNAQ, WASL, and RAC1

The Multi-Kinase Inhibitor Afatinib Serves As a Novel Candidate for the Treatment of Human Uveal Melanoma

The role of circulating tumor DNA in melanomas of the uveal tract

CANT1 Lncrna Triggers Efficient Therapeutic Efficacy by Correcting Aberrant Lncing Cascade in Malignant Uveal Melanoma.

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

Targeting Of Ccn2 Suppresses Tumor Progression And Improves Chemo-Sensitivity In Urothelial Bladder Cancer

Study of Cinobufagin As a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway

Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma

Targeted OUM1/PTPRZ1 silencing and synergetic CDT/enhanced chemical therapy toward uveal melanoma based on a dual-modal imaging-guided manganese metal–organic framework nanoparticles

Targeted Silencing Of Mart-1 Gene Expression By Rna Interference Enhances The Migration Ability Of Uveal Melanoma Cells

The Inhibitory Effect of a New Scfv/tp Protein As Sirna Delivery System to Target Hwapl in Cervical Carcinoma

The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma

Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells

Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft